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Nasopharayngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated malignancy. It is
known that microRNAs are implicated in the progression of NPC. However, the role of miR-204 in
NPC is poorly understood. In this study, we found that miR-204 was down-regulated in NPC cells
and tissues. Low-level expression of miR-204 was signiﬁcantly associated with a more aggressive
and poor prognostic phenotype of NPC. We further found that EBV-encoded latent membrane pro-
tein 1 (LMP-1) suppressed miR-204 expression by activating Stat-3. Cdc42 was identiﬁed as a direct
target of miR-204. Mir-204 inhibited EBV positive C666-1 cell invasion andmetastasis partly through
targeting cdc42.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nasopharyngeal carcinoma (NPC), though rare in the Western
world (1 per 100,000), is the most frequent head and neck tumor
in South China, where the incidence peaks at 50 per 100,000
[1,2]. NPC is tightly associated with the Epstein–Barr virus (EBV).
It is well documented that with the clonal expansion of EBV-
infected progenitor cells, constitutive expression of viral latent
genes may lead to the accumulation of multiple genetic changes
that subsequently contribute to the initiation and progression of
this cancer [3,4].
MicroRNAs (miRNAs or miRs), a group of small (22 nt)
non-coding RNAs, can interfere with gene expression through deg-
radation of mRNA or inhibition of the translational machinery [5].
Dysregulation of miRNAs is often found in cancer pathogenesis
where they function either as oncogenes or as tumor suppressors
[6]. To date, a growing number of miRNAs have been implicated
in different stages of NPC [7]. A previous report documented thatmiR-204 was down-regulated in NPC tissues [7]. However, the bio-
logical functions of miR-204 in the control of NPC progression have
not been well characterized.
Herein, we report that miR-204 is down-regulated in NPC cells,
especially in the EBV positive cell line C666-1. Furthermore, we
examined the role of LMP-1 in the regulation of miR-204. More
importantly, we provide evidence that miR-204 inhibits NPC cells
invasiveness and metastasis through targeting the cell division
cycle 42 (cdc42) protein.
2. Materials and methods
2.1. Patient samples
Written informed consent was obtained from all individual pa-
tients who participated in the study. All human primary NPC spec-
imens and non-tumor nasopharyngeal epithelial samples were
obtained from the Cancer Center of GuangzhouMedical University;
Department of Pathology, Guangzhou university of Chinese
Medicine; Department of Pathology, the Third Afﬁliated Hospital
of Sun Yat-Sen University and from the Afﬁliated Hospital of
Guangdong Medical College. Individual patients with NPC were
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to the criteria established by the UICC/AJCC staging system in
2002. The Institute Research Medical Ethics Committee of Guangz-
hou Medical University granted approval for this study.
2.2. Cell culture
The NPC cell lines (HNE-1, 5-8F, HONE-1, C666-1) were main-
tained in RPMI-1640 supplemented with 10% fetal bovine serum
(FBS). NP69, an immortalized nasopharyngeal epithelium cell line,
was cultured in keratinocyte serum-free medium (keratinocyte-
SFM; Gibco). 293T cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% FBS. All cell lines were
maintained at 37 C in a humidiﬁed atmosphere with 5% CO2.
2.3. Lentivirus production and transduction
The pLV-has-miR-204 plasmid and the negative control pLV-
miRNA-vector were purchased from Biosettia Inc. (Biosettia, San
Diego, USA). The viruses were packaged in 293T cells according
to standard protocols and the virus particles were harvested 72 h
later. The packaged lentiviruses were named LV-miR-204. The
empty lentiviral vector LV-con was used as a control. C666-1 cells
were infected with virus particles plus 8 lg/ml Polybrene (Sigma,
St. Louis, Missouri, USA). Infected cells were selected with puromy-
cin for up to 7 days.
2.4. Oligonucleotide transfection
SiRNA duplex oligonucleotides targeting human Stat-3 mRNA
50-aacaucugccuagaucggcua-30 and human LMP-1 mRNA 50-aagag
ccuucucuguccacu-30 were synthesized by GeneChem (Shanghai,
China). Synthesized RNA duplexes of scramble miRNA, miR-204
and their inhibitors anti-scramble and anti-miR-204 were obtained
from Ribobo (Guangzhou, China). Full-length cdc42 cDNA entirelyTable 1
Correlation of miR-204 expression in tissue with patients clinicop
Variables miR-204
All case (n = 275) Low express
Age(years)
<60 104 59
=60 171 78
Sex
Male 136 69
Female 139 68
Smoking
Yes 109 57
No 166 80
EBV
Positive 202 111
Negative 73 26
T classiﬁcation
T1–T2 118 54
T3–T4 157 83
N classiﬁcation
N0–N1 109 67
N2–N3 166 70
M classiﬁcation
M0 129 67
M1 146 70
TNM clinical stage
I, II 123 47
III, IV 152 90lacking the 30-UTR was purchased from GeneCopeia (Rockville, MD,
USA) and subcloned into the eukaryotic expression vector
pcDNA3.1 (Invitrogen). pcDNA3.1-LMP-1 and pcDNA3.1-Stat-3
were kind gifts from Dr. Ming Li (Sun Yat-Sen University,
Guangzhou, China). Oligonucleotide transfection was performed
with Lipofectamine 2000 reagent (Invitrogen).
2.5. Luciferase reporter assay
The 30-UTR untranslated region of cdc42 was ampliﬁed by
PCR and cloned downstream of the ﬁreﬂy luciferase gene in
the pGL3 vector (Promega). The vector was named wild-type
(wt) 30-UTR. Site-directed mutagenesis of the miR-204 binding
site in cdc42 30-UTR was performed using the Quick change
site-directed mutagenesis kit (Stratagene, Cedar Creek, USA)
and named mutant (mt) 30-UTR. For reporter assays, wt or mt
30-UTR vector and the control vector pRL-CMV (Promega) were
cotransfected. The luciferase assay was performed by using the
dual Luciferase reporter assay system (Promega) 48 h after
transfection.
2.6. RNA isolation and quantitative real-time PCR
Total RNA was extracted from cells with TRIzol reagent (Invitro-
gen). cDNA was synthesized with the PrimeScript RTreagent Kit
(Promega, Madison, WI, USA). For miR-204, reverse transcription
and qRT-PCR reactions were performed by means of a qSYBR-
green-containing PCR kit (GenePharma, Shanghai, China), and U6
snRNA was used as an endogenous control. The primer sequences
are provided in Table 1.
2.7. Cell migration and invasion assays
Cell migration and invasion assays were performed as previ-
ously described [8].athological variables in 275 cases of NPC.
P value⁄
ion (n = 137) High expression (n = 138)
45 0.096
93
67 0.857
71
52 0.588
86
91 0.007⁄
47
64 0.296
74
42 0.003⁄
96
62 0.589
76
76 0.001⁄
62
Fig. 1. MiR-204, decreased by LMP-1, was frequently downregulated in NPC tissues
and cell lines. (A) The expression levels of miR-204 were lower in NPC tissues,
compared with non-cancerous nasopharyngeal tissue samples, as indicated by Real-
time PCR analysis (P < 0.01). (B) The expression level of miR-204 in NP-69 and NPC
cell lines. (C) The expression level of LMP-1 in NP-69 and NPC cell lines. (D)
Exogenetic overexpression of LMP-1 in NP-69 cells. (E) Overexpression of LMP-1
decreased both the primary and mature transcript levels of miR-204 in NP-69 cells.
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The primary antibodies Cdc42, Stat3, phosphorylated Stat-3,
Vimentin, E-cadherin, MMP-9, and GAPDH were purchased from
Santa Cruz (USA). Primary antibody LMP-1 was purchased from
Bethyl Laboratories, Inc. Western blot, Immunoﬂuorescence and
Immunohistochemistry assays were performed as previously de-
scribed [8].
2.9. ChIP-PCR
DNA–protein complexes were immunoprecipitated from C666-
1 cells that were transfected with Stat-3 cDNA by using the Chro-
matin Immunoprecipitation Kit (Millipore, Billerica, MA, USA),
according to the manufacturer’s protocol with the following poly-
clonal antibodies: anti-p-Stat-3 or normal mouse IgG (Millipore).
The precipitated DNA was subjected to qPCR analysis by using spe-
ciﬁc primers to amplify across the miR-204 promoter region. The
primers used in the PCR reactions were previously described [9].
Finally, the data were analyzed using the 244Ct method [10].
2.10. In vivo growth and metastasis assay
For the in vivo tumor growth studies, 1  106 C666-1 cells, sta-
bly expressing miR-204, or the control vector, were injected subcu-
taneously in the upper back of BALB/C-nu/nu athymic nude mice.
The length and width of the tumors were measured every 5 days
using a digital caliper and tumor volumes were calculated using
the formula Volume (mm3) = L W2/2 (length L, mm; width W,
mm). After 25 days, tumor samples were carefully removed and
weighed. The experimental metastasis studies were conducted as
previously described [11]. All animal procedures were performed
in accordance with institutional guidelines.
2.11. Statistical analysis
All data were analyzed using SPSS 13.0 software (SPSS, Chicago,
IL, USA). Survival analysis was performed using the Kaplan–Meier
method. A log rank test was used to compare different survival
curves. A two-tailed Student’s t-test was used for the comparison
between two independent groups. One-way ANOVA was used to
determine the differences between groups. P values of <0.05 were
considered as statistically signiﬁcant.
3. Results
3.1. Lower levels of miR-204 are frequently detected in NPC tissues and
associated with NPC progression and poor prognosis
Real-time PCR analysis indicated that the expression levels of
miR-204 were lower in NPC tissues (n = 26) when compared with
non-cancerous nasopharyngeal tissue samples (n = 18) (P < 0.01;
Fig. 1A). To further investigate the clinicopathological and prognos-
tic signiﬁcance of miR-204 in patients with NPC, the levels of
miR-204 in a large cohort study of 275 NPC patient tissues were
examined by real-time PCR. We differentiated tumors with low-le-
vel expression of miR-204 from tumors with high-level expression
of miR-204 by choosing the median value of all 275 NPC samples
as the cut-off point. Thus, 137/275 (50.2%) NPC patients had low-le-
vel expression of miR-204, while 138/275 (49.8%) NPC patients had
high-level expression of miR-204. As shown in Table 1, low expres-
sion of miR-204 closely correlated with EBV infection status (posi-
tive vs. negative) (P = 0.007), lymph node metastasis (N
classiﬁcation, N0–N1 vs. N2–N3) (P = 0.003) and more advanced
clinical stages (Clinical stage, I–II vs. III–IV) (P = 0.001). Nosigniﬁcant association was found between miR-204 expression
and other clinicopathological features, such as the patient’s gender,
age, smoking status, T classiﬁcation and M classiﬁcation.
Kaplan–Meier analysis revealed that a low-level expression of
miR-204 was associated with a short survival time of patients with
NPC (Table 2, P < 0.05).
3.2. The LMP-1-mediated Stat-3 pathway is involved in miR-204
downregulation
When we found that miR-204 correlates with EBV infection
status in NPC patients, we further investigated the mechanism
of EBV-regulated miR-204 expression. The expression of miR-
204 was examined in NPC cell lines, including HNE-1, 5-8F,
HONE-1, C666-1 and nasopharyngeal epithelial (NPE) cell line
NP-69. The real-time PCR assay showed that the expression level
of miR-204 was signiﬁcantly lower in NPC cell lines when com-
pared with NPE cell line NP-69. Importantly, the EBV-positive
cell line C666-1 showed the lowest level of miR-204 (P < 0.05,
Fig. 1B). Furthermore, we found that C666-1 cells expressed
higher levels of LMP-1, when compared with other NPC cell lines
and NP-69 (Fig. 1C). We next tested whether exogenetic overex-
pression of LMP-1 affected miR-204 expression. NP-69 cells were
transiently transfected with pcDNA3.1-LMP-1 or empty vector
pcDNA3.1 and the over-expression efﬁciency of LMP-1 was con-
ﬁrmed by Western blot analysis (Fig. 1D). A qRT-PCR assay dem-
onstrated that miR-204 expression in NP-69-pcDNA3.1-LMP-1
Table 2
Kaplan–Meier survival analysis of overall survival duration in 275 NPC patients according to miR-204 expression.
Fig. 2. The Stat-3 pathway was involved in LMP-1-mediated miR-204 downregu-
lation. (A) si-ctrl or si-Stat-3 was used to suppress the expression of Stat-3 in C666-
1 cells. (B) Knock down of Stat-3 increase the expression level of miR-204 in C666-1
cells. (C) Overexpression of Stat-3 dose-dependently inhibited miR-204 promoter
activity in NP-69 cells. (D) Q-PCR analysis indicated that p-Stat-3 could bind more
miR-204 promoter region than that in control group (normal human IgG) in C666-1
cells (⁄P < 0.05). (E) LMP-1 increased the expression of phos-Stat-3, but not their
total protein levels.
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levels, when compared with NP-69-pcDNA3.1 cells (P < 0.05,
Fig. 1E).
The foregoing results suggested that the LMP-1-mediated
down-regulation of miR-204 occurred via a transcriptional mecha-
nism. It has been well known that LMP-1 can activate the Stat-3
signaling pathway [12,13]. In a previous study it has been docu-
mented that the expression of miR-204 was controlled by Stat-3
[9]. We then asked whether Stat-3 also regulated miR-204 in
NPC. To examine the role of Stat-3 in regulating miR-204 expres-
sion in NPC cells, we ﬁrst used siRNA to suppress the expression
of Stat-3 in C666-1 cells (Fig. 2A). Q-PCR analysis indicated that
miR-204 expression was markedly increased in Stat-3 knockdown
C666-1 cells (Fig. 2B). Furthermore, by using a luciferase assay we
found that the overexpression of Stat-3 dose-dependently inhib-
ited miR-204 promoter activity in NP-69 cells (Fig. 2C). In a subse-
quent experiment, we used chromatin immunoprecipitation
combined with qPCR analysis to conﬁrm that Stat-3 could bind
to the miR-204 promoter site and suppress its expression in
C666-1 cells (Fig. 2D). Finally, we observed that LMP-1 increased
the expression of phos-Stat-3, but not the total protein levels
(Fig. 2E). Taken together, these results demonstrated that LMP-1
suppressed the expression of miR-204 through activation of the
Stat-3 pathway.
3.3. Restoration of miR-204 inhibits NPC cell migration and invasion
in vitro
The effect of miR-204 on the migration of C666-1 cells was
characterized by the transwell assay, which showed that exoge-
netic overexpression of miR-204 by a lentiviral vector caused a
suppression of cell migration in the C666-1 cells (P < 0.05,
Fig. 3A). The matrigel invasion assay demonstrated that exoge-
netic overexpression of miR-204 markedly reduced the invasive-
ness of C666-1 cells (P < 0.05, Fig. 3B). Furthermore, we
examined whether miR-204 affected the expression levels of
proteins involved in invasion and metastasis of NPC cells. We
found that over-expression of miR-204 suppressed Vimentin
Fig. 3. Restoration of miR-204 inhibits migration and invasion, while anti-miR-204 induced invasive phenotypes in C666-1 cells. (A) and (B) Exogenetic overexpression of
miR-204 suppressed migration and invasion in C666-1 cells. (C) and (D) Overexpression of miR-204 inhibit Vimentin and MMP-9 expression, but increased E-cadherin
expression in C666-1 cells, as determined by Western blot and immunoﬂuorescence, respectively. (E) and (F) Inhibition of miR-204 by anti-miR-204 promoted migration and
invasion in C666-1 cells. (G) Inhibition of miR-204 increased Vimentin and MMP-9 expression, but decreased E-cadherin expression in C666-1 cells.
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determined by Western blot analysis and immunoﬂuorescence(Fig. 3C and D). In contrast, anti-miR-204 induced cell invasive
phenotypes in C666-1 cells (Fig. 3E–G).
Fig. 4. Cdc42 was a direct target of miR-204. (A) Sequence alignment of miR-204 and the cdc42 30-UTR, which contains one predicted miR-204-binding site (indicated in red)
and mutant cdc42 sequence (indicated in blue). (B) Luciferase assay in C666-1 cells co-transfected with miR-204 and a luciferase reporter containing the cdc42 30-UTR (WT)
or a mutant (Mut). (C) MiR-204 transfection affects cdc42 protein levels. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 5. Cdc42 was potentially involved in miR-204-regulated NPC cell invasiveness. (A) and (B) Overexpression of cdc42 rescued miR-204 induced inhibition of cell migration
and invasion. (C) Ectopic expression of cdc42 could counteract the effect of miR-204 on cdc42, E-cadherin, Vimentin and MMP-9.
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Two computational algorithms, TargetScan and miRanda, were
used to search for potential miR-204 target genes. Among the
mRNAs containing miR-204 recognition sites in their 30UTRs, we
focused on cdc42, a protein involved in tumorigenesis and progres-
sion of NPC [14,15]. To verify that cdc42 is a direct target of miR-
204, cdc42 wild-type (WT) or mutant 30UTR was subcloned intoa luciferase reporter vector and co-transfected with miR-204 or
scrambled control into C666-1 cells (Fig. 4A). MiR-204 signiﬁcantly
inhibited the luciferase activity of the cdc42WT 30UTR but not that
of the mutant in C666-1 cells (Fig. 4B). Furthermore, overexpres-
sion of miR-204 signiﬁcantly downregulated cdc42 protein levels
(Fig. 4C), though did not affect cdc42 mRNA levels (data not
shown). These results indicate that cdc42 is a target gene of miR-
204.
Fig. 6. Restoration of miR-204 attenuated the growth and metastasis of C666-1 cells in vivo. (A) and (B) Stable transfection of miR-204 into C666-1 cells resulted in decreased
growth and tumor weight of subcutaneous xenograft tumors in nude mice. (C) Immunohistochemistry assay showed that miR-204 decreased expression levels of cdc42,
Vimentin and MMP-9, but increased expression level of E-cadherin in vivo. (D) C666-1 cells stably transfected with miR-204 established smaller lung metastatic colonies than
mock group.
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invasiveness
To further examine whether miR-204 exerts its tumor suppres-
sor function through inhibition of cdc42, we performed rescue
studies. C666-1 cells were infected with miR-204 or scrambledcontrol followed by transfection with cdc42 vector (without
30UTR). We found that co-transfection with a cdc42-overexpress-
ing vector partially blocked the miR-204 induced inhibition of cell
migration and invasion (Fig. 5A and B). Western blot assay showed
that the miR-204-induced downregulation of cdc42 was rescued
upon the introduction of cdc42, and the levels of MMP-9 and
L. Ma et al. / FEBS Letters 588 (2014) 1562–1570 1569Vimentin were altered in a similar manner. In addition, ectopic
expression of cdc42 could counteract the promotive effect of
miR-204 on E-cadherin (Fig. 5C).
3.6. Overexpression of miR-204 attenuated the growth and metastasis
of NPC cells in vivo
We next investigated the efﬁcacy of miR-204 against tumor
growth and metastasis in vivo. Stable transfection of miR-204 into
C666-1 cells resulted in decreased growth and tumor weight of
subcutaneous xenograft tumors in nude mice, when compared
with those stably transfected with empty vector (Fig. 6A and B).
Using Immunohistochemistry, we found that the expression of
cdc42, Vimentin and MMP-9 were also reduced by stable transfec-
tion of miR-204. However, the expression of E-cadherin was ele-
vated in miR-204-treated group (Fig. 6C). In the experimental
metastasis studies, C666-1 cells stably transfected with miR-204
established smaller lung metastatic colonies than mock group
(Fig. 6D). These results suggested that miR-204 could inhibit the
growth and metastasis of NPC cells in vivo.
4. Discussion
MiR-204 has been reported to function as a tumor suppressor
and low-level expression of miR-204 is associated with a poor
prognostic phenotype in patients with cancer. In addition, miR-
204 is located at the cancer-associated genomic region 9q21.1–
q22.3 locus in human head and neck cancer [16–18].
NPC, notorious for its highly metastatic nature, is a unique EBV-
associated epithelial malignancy. LMP1 protein is detected in
approximately 60% of tissue samples from NPC patients [19,20],
while LMP1 mRNA is detected in nasopharyngeal swabs in over
90% of NPC patients by RT-PCR [21,22]. The frequent expression
of LMP1 in NPC suggests a role for this viral oncoprotein as a key
molecule in NPC pathogenesis [23–25]. In this study, we investi-
gated the molecular mechanism of LMP-1-mediated miR-204
expression. We found an inverse correlation between the expres-
sion of LMP-1 and miR-204 in NPC cells. LMP1 over-expression
or silencing signiﬁcantly down or up-regulated the miR-204
expression in NP-69 and C666-1 cells, respectively. LMP-1 expres-
sion and Stat-3 activation is well documented in epithelial cells la-
tently infected with EBV. Recently, this LMP-1-mediated Stat-3
activation was conﬁrmed in a transgenic mouse model with spe-
ciﬁc epithelial expression of LMP-1 [26]. Results from a previous
study suggest that activation of Stat-3 in pulmonary arterial hyper-
tension suppresses miR-204 expression [9]. We speculated that
LMP-1 might regulate the expression of miR-204 through the
Stat-3 pathway. Our observation revealed that LMP-1 activated
the Stat-3 pathway through increasing the expression of phos-
Stat-3. We further found that by knocking down Stat-3, miR-204
expression in C666-1 cells could be increaed. Finally, chromatin
immunoprecipitation combined with qPCR analysis were used to
conﬁrm that Stat-3 could bind to the miR-204 promoter site and
suppress its expression in C666-1 cells.
Cdc42 was identiﬁed as a direct target of miR-204 in the present
study through dual-ﬁreﬂy luciferase reporter assay and Western
blot analysis. Being a member of the Rho GTPases, cdc42 is known
to regulate intracellular activities such as focal complex formation,
integrin localization, adhesion, cell morphology, and MMP expres-
sion [27]. Knockdown of cdc42 inhibited cell motility, but in-
creased apoptosis in NPC cells [14,28], suggesting that cdc42 is
involved in progression and metastasis in NPC. Our results showed
that exogenous introduction of cdc42 can partly rescue the tumor-
suppressive effect of miR-204 in C666-1 cells and miR-204 down-
regulation was correlated with cdc42 upregulation in NPC tissues.These results indicate that the downregulation of miR-204 in NPC
may promote metastasis through the upregulation of cdc42
expression.
In summary, our present work indicates that low miR-204 lev-
els induced by EBV via LMP-1 promote EBV positive cells migration
and invasion. Our ﬁndings on miR-204 suggest that this microRNA
could be employed as an effective therapeutic target for NPC in the
future.
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